Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

Udaya S. Tantry, Laurent Bonello, D. Aradi, Matthew J. Price, Young Hoon Jeong, Dominick J. Angiolillo, Gregg W. Stone, Nick Curzen, Tobias Geisler, Jurrien Ten Berg, Ajay Kirtane, Jolanta Siller-Matula, Elisabeth Mahla, Richard C. Becker, Deepak L. Bhatt, Ron Waksman, Sunil V. Rao, Dimitrios Alexopoulos, Rossella Marcucci, Jean Luc Reny & 3 others Dietmar Trenk, Dirk Sibbing, Paul A. Gurbel

Research output: Contribution to journalArticle

553 Citations (Scopus)

Abstract

Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y 12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y 12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy.

Original languageEnglish
Pages (from-to)2261-2273
Number of pages13
JournalJournal of the American College of Cardiology
Volume62
Issue number24
DOIs
Publication statusPublished - Dec 17 2013

Fingerprint

Adenosine Diphosphate
Blood Platelets
Ischemia
Hemorrhage
Platelet Function Tests
Percutaneous Coronary Intervention
Therapeutics
Practice Guidelines
Aspirin

Keywords

  • adenosine diphosphate
  • bleeding
  • consensus
  • ischemia
  • platelet reactivity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. / Tantry, Udaya S.; Bonello, Laurent; Aradi, D.; Price, Matthew J.; Jeong, Young Hoon; Angiolillo, Dominick J.; Stone, Gregg W.; Curzen, Nick; Geisler, Tobias; Ten Berg, Jurrien; Kirtane, Ajay; Siller-Matula, Jolanta; Mahla, Elisabeth; Becker, Richard C.; Bhatt, Deepak L.; Waksman, Ron; Rao, Sunil V.; Alexopoulos, Dimitrios; Marcucci, Rossella; Reny, Jean Luc; Trenk, Dietmar; Sibbing, Dirk; Gurbel, Paul A.

In: Journal of the American College of Cardiology, Vol. 62, No. 24, 17.12.2013, p. 2261-2273.

Research output: Contribution to journalArticle

Tantry, US, Bonello, L, Aradi, D, Price, MJ, Jeong, YH, Angiolillo, DJ, Stone, GW, Curzen, N, Geisler, T, Ten Berg, J, Kirtane, A, Siller-Matula, J, Mahla, E, Becker, RC, Bhatt, DL, Waksman, R, Rao, SV, Alexopoulos, D, Marcucci, R, Reny, JL, Trenk, D, Sibbing, D & Gurbel, PA 2013, 'Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding', Journal of the American College of Cardiology, vol. 62, no. 24, pp. 2261-2273. https://doi.org/10.1016/j.jacc.2013.07.101
Tantry, Udaya S. ; Bonello, Laurent ; Aradi, D. ; Price, Matthew J. ; Jeong, Young Hoon ; Angiolillo, Dominick J. ; Stone, Gregg W. ; Curzen, Nick ; Geisler, Tobias ; Ten Berg, Jurrien ; Kirtane, Ajay ; Siller-Matula, Jolanta ; Mahla, Elisabeth ; Becker, Richard C. ; Bhatt, Deepak L. ; Waksman, Ron ; Rao, Sunil V. ; Alexopoulos, Dimitrios ; Marcucci, Rossella ; Reny, Jean Luc ; Trenk, Dietmar ; Sibbing, Dirk ; Gurbel, Paul A. / Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. In: Journal of the American College of Cardiology. 2013 ; Vol. 62, No. 24. pp. 2261-2273.
@article{c3fb93193d14462f8bf2abe89706329a,
title = "Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding",
abstract = "Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y 12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y 12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy.",
keywords = "adenosine diphosphate, bleeding, consensus, ischemia, platelet reactivity",
author = "Tantry, {Udaya S.} and Laurent Bonello and D. Aradi and Price, {Matthew J.} and Jeong, {Young Hoon} and Angiolillo, {Dominick J.} and Stone, {Gregg W.} and Nick Curzen and Tobias Geisler and {Ten Berg}, Jurrien and Ajay Kirtane and Jolanta Siller-Matula and Elisabeth Mahla and Becker, {Richard C.} and Bhatt, {Deepak L.} and Ron Waksman and Rao, {Sunil V.} and Dimitrios Alexopoulos and Rossella Marcucci and Reny, {Jean Luc} and Dietmar Trenk and Dirk Sibbing and Gurbel, {Paul A.}",
year = "2013",
month = "12",
day = "17",
doi = "10.1016/j.jacc.2013.07.101",
language = "English",
volume = "62",
pages = "2261--2273",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "24",

}

TY - JOUR

T1 - Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

AU - Tantry, Udaya S.

AU - Bonello, Laurent

AU - Aradi, D.

AU - Price, Matthew J.

AU - Jeong, Young Hoon

AU - Angiolillo, Dominick J.

AU - Stone, Gregg W.

AU - Curzen, Nick

AU - Geisler, Tobias

AU - Ten Berg, Jurrien

AU - Kirtane, Ajay

AU - Siller-Matula, Jolanta

AU - Mahla, Elisabeth

AU - Becker, Richard C.

AU - Bhatt, Deepak L.

AU - Waksman, Ron

AU - Rao, Sunil V.

AU - Alexopoulos, Dimitrios

AU - Marcucci, Rossella

AU - Reny, Jean Luc

AU - Trenk, Dietmar

AU - Sibbing, Dirk

AU - Gurbel, Paul A.

PY - 2013/12/17

Y1 - 2013/12/17

N2 - Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y 12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y 12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy.

AB - Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet reactivity to adenosine diphosphate (ADP) associated with post-percutaneous coronary intervention ischemic events for various platelet function tests (PFTs). Updated American and European practice guidelines have issued a Class IIb recommendation for PFT to facilitate the choice of P2Y 12 receptor inhibitor in selected high-risk patients treated with percutaneous coronary intervention, although routine testing is not recommended (Class III). Accumulated data from large studies underscore the importance of high on-treatment platelet reactivity to ADP as a prognostic risk factor. Recent prospective randomized trials of PFT did not demonstrate clinical benefit, thus questioning whether treatment modification based on the results of current PFT platforms can actually influence outcomes. However, there are major limitations associated with these randomized trials. In addition, recent data suggest that low on-treatment platelet reactivity to ADP is associated with a higher risk of bleeding. Therefore, a therapeutic window concept has been proposed for P2Y 12 inhibitor therapy. In this updated consensus document, we review the available evidence addressing the relation of platelet reactivity to thrombotic and bleeding events. In addition, we propose cutoff values for high and low on-treatment platelet reactivity to ADP that might be used in future investigations of personalized antiplatelet therapy.

KW - adenosine diphosphate

KW - bleeding

KW - consensus

KW - ischemia

KW - platelet reactivity

UR - http://www.scopus.com/inward/record.url?scp=84890025521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890025521&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2013.07.101

DO - 10.1016/j.jacc.2013.07.101

M3 - Article

VL - 62

SP - 2261

EP - 2273

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 24

ER -